ES2725881T3 - Nuevos derivados de imidazolidin-2,4-diona - Google Patents
Nuevos derivados de imidazolidin-2,4-diona Download PDFInfo
- Publication number
- ES2725881T3 ES2725881T3 ES13900705T ES13900705T ES2725881T3 ES 2725881 T3 ES2725881 T3 ES 2725881T3 ES 13900705 T ES13900705 T ES 13900705T ES 13900705 T ES13900705 T ES 13900705T ES 2725881 T3 ES2725881 T3 ES 2725881T3
- Authority
- ES
- Spain
- Prior art keywords
- trifluoromethyl
- dimethyl
- phenyl
- methylsulfonyl
- dioxoimidazolidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical class O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 title description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 231
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 45
- 150000001721 carbon Chemical group 0.000 claims abstract description 40
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 33
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 32
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 31
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 25
- 125000005843 halogen group Chemical group 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 13
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 6
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 6
- 150000002367 halogens Chemical class 0.000 claims abstract description 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims abstract description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 4
- -1 1- (4- (5,5-dimethyl-3- (4- (methylsulfonyl) -3- (trifluoromethyl) phenyl) -2,4-dioxoimidazolidin-1-yl) but-2- en-1-yl) -1H-pyrazol-4-yl Chemical group 0.000 claims description 83
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 claims description 31
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 12
- 102000001307 androgen receptors Human genes 0.000 claims description 12
- 108010080146 androgen receptors Proteins 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 206010060862 Prostate cancer Diseases 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- CIUXWMZWYIONRO-UHFFFAOYSA-N 4-[3-[(Z)-4-[3,5-dimethyl-4-[4-methylsulfonyl-3-(trifluoromethyl)phenyl]pyrazol-1-yl]but-2-enyl]-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile Chemical compound CC1=NN(C(=C1C1=CC(=C(C=C1)S(=O)(=O)C)C(F)(F)F)C)CC=C/CN1C(N(C(C1(C)C)=O)C1=CC(=C(C#N)C=C1)C(F)(F)F)=O CIUXWMZWYIONRO-UHFFFAOYSA-N 0.000 claims description 6
- HMNWTOLFPWTSLC-UHFFFAOYSA-N 4-[3-[(Z)-4-[4-(3-chloro-4-methylsulfonylphenyl)-2-oxopyrrolidin-1-yl]but-2-enyl]-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile Chemical compound ClC=1C=C(C=CC1S(=O)(=O)C)C1CC(N(C1)CC=C/CN1C(N(C(C1(C)C)=O)C1=CC(=C(C#N)C=C1)C(F)(F)F)=O)=O HMNWTOLFPWTSLC-UHFFFAOYSA-N 0.000 claims description 6
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 6
- LWFVRJYWAVMIMJ-UHFFFAOYSA-N 5-[3-[(Z)-4-[4-(3-chloro-4-methylsulfonylphenyl)pyrazol-1-yl]but-2-enyl]-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound ClC=1C=C(C=CC1S(=O)(=O)C)C=1C=NN(C1)CC=C/CN1C(N(C(C1(C)C)=O)C=1C=C(C(=NC1)C#N)C(F)(F)F)=O LWFVRJYWAVMIMJ-UHFFFAOYSA-N 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 230000001419 dependent effect Effects 0.000 claims description 5
- 229940088597 hormone Drugs 0.000 claims description 5
- 239000005556 hormone Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- NUFPLPFEPPLHAS-UHFFFAOYSA-N 4-[3-[(Z)-4-[3-(3-chloro-4-methylsulfonylphenyl)-2-oxoimidazolidin-1-yl]but-2-enyl]-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile Chemical compound ClC=1C=C(C=CC1S(=O)(=O)C)N1C(N(CC1)CC=C/CN1C(N(C(C1(C)C)=O)C1=CC(=C(C#N)C=C1)C(F)(F)F)=O)=O NUFPLPFEPPLHAS-UHFFFAOYSA-N 0.000 claims description 4
- NAFQNTULXDLNAB-UHFFFAOYSA-N 5,5-dimethyl-3-[4-methylsulfonyl-3-(trifluoromethyl)phenyl]-1-[(Z)-4-[4-[4-methylsulfonyl-3-(trifluoromethyl)phenyl]-2-oxopyrrolidin-1-yl]but-2-enyl]imidazolidine-2,4-dione Chemical compound CC1(C(N(C(N1CC=C/CN1C(CC(C1)C1=CC(=C(C=C1)S(=O)(=O)C)C(F)(F)F)=O)=O)C1=CC(=C(C=C1)S(=O)(=O)C)C(F)(F)F)=O)C NAFQNTULXDLNAB-UHFFFAOYSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- IKIYOBLVGDFJEF-UHFFFAOYSA-N 4-[1-[(Z)-4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-2,4-dioxoimidazolidin-1-yl]but-2-enyl]pyrazol-4-yl]-2-(trifluoromethyl)benzonitrile Chemical compound C(#N)C1=C(C=C(C=C1)C=1C=NN(C1)CC=C/CN1C(N(C(C1(C)C)=O)C1=CC(=C(C#N)C=C1)C(F)(F)F)=O)C(F)(F)F IKIYOBLVGDFJEF-UHFFFAOYSA-N 0.000 claims description 3
- RTEPASURWXLBBA-UHFFFAOYSA-N 5,5-dimethyl-3-[4-methylsulfonyl-3-(trifluoromethyl)phenyl]-1-[(Z)-4-[4-[4-methylsulfonyl-3-(trifluoromethyl)phenyl]pyrazol-1-yl]but-2-enyl]imidazolidine-2,4-dione Chemical compound CC1(C(N(C(N1CC=C/CN1N=CC(=C1)C1=CC(=C(C=C1)S(=O)(=O)C)C(F)(F)F)=O)C1=CC(=C(C=C1)S(=O)(=O)C)C(F)(F)F)=O)C RTEPASURWXLBBA-UHFFFAOYSA-N 0.000 claims description 3
- XPNIEZCKJYBXPI-UHFFFAOYSA-N 5-[4,4-dimethyl-3-[(Z)-4-[4-[4-methylsulfonyl-3-(trifluoromethyl)phenyl]pyrazol-1-yl]but-2-enyl]-2,5-dioxoimidazolidin-1-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound CC1(N(C(N(C1=O)C=1C=C(C(=NC1)C#N)C(F)(F)F)=O)CC=C/CN1N=CC(=C1)C1=CC(=C(C=C1)S(=O)(=O)C)C(F)(F)F)C XPNIEZCKJYBXPI-UHFFFAOYSA-N 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- QCSUALZAYHNPLU-FPLPWBNLSA-N 3-(3-chloro-4-methylsulfonylphenyl)-1-[(Z)-4-[5,5-dimethyl-3-[4-methylsulfonyl-3-(trifluoromethyl)phenyl]-2-oxoimidazolidin-1-yl]but-2-enyl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound ClC=1C=C(C=CC=1S(=O)(=O)C)N1C(N(C(C1=O)(C)C)C\C=C/CN1C(N(CC1(C)C)C1=CC(=C(C=C1)S(=O)(=O)C)C(F)(F)F)=O)=O QCSUALZAYHNPLU-FPLPWBNLSA-N 0.000 claims description 2
- USFPWKDOAPUVDX-ARJAWSKDSA-N 4-[1-[(Z)-4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-2,4-dioxoimidazolidin-1-yl]but-2-enyl]pyrrolidin-3-yl]-2-(trifluoromethyl)benzonitrile Chemical compound C(#N)C1=C(C=C(C=C1)N1C(N(C(C1=O)(C)C)C\C=C/CN1CC(CC1)C1=CC(=C(C#N)C=C1)C(F)(F)F)=O)C(F)(F)F USFPWKDOAPUVDX-ARJAWSKDSA-N 0.000 claims description 2
- CFPHXUHDFBGHIC-UHFFFAOYSA-N 4-[3-[(Z)-4-[4-(3,4-dichlorophenyl)triazol-1-yl]but-2-enyl]-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile Chemical compound ClC=1C=C(C=CC1Cl)C=1N=NN(C1)CC=C/CN1C(N(C(C1(C)C)=O)C1=CC(=C(C#N)C=C1)C(F)(F)F)=O CFPHXUHDFBGHIC-UHFFFAOYSA-N 0.000 claims description 2
- DPDOQQRLOXUFQY-UHFFFAOYSA-N 4-[3-[(Z)-4-[4-(4-fluoro-3-methylphenyl)triazol-1-yl]but-2-enyl]-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile Chemical compound FC1=C(C=C(C=C1)C=1N=NN(C1)CC=C/CN1C(N(C(C1(C)C)=O)C1=CC(=C(C#N)C=C1)C(F)(F)F)=O)C DPDOQQRLOXUFQY-UHFFFAOYSA-N 0.000 claims description 2
- HCXGHJUIVMZIME-UHFFFAOYSA-N 4-[4,4-dimethyl-3-[(Z)-4-[3-[4-methylsulfonyl-3-(trifluoromethyl)phenyl]-2-oxoimidazolidin-1-yl]but-2-enyl]-2,5-dioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile Chemical compound CC1(N(C(N(C1=O)C1=CC(=C(C#N)C=C1)C(F)(F)F)=O)CC=C/CN1C(N(CC1)C1=CC(=C(C=C1)S(=O)(=O)C)C(F)(F)F)=O)C HCXGHJUIVMZIME-UHFFFAOYSA-N 0.000 claims description 2
- LNPSTXLOXOUAHD-UHFFFAOYSA-N 4-[4,4-dimethyl-3-[(Z)-4-[4-[4-methylsulfonyl-3-(trifluoromethyl)phenyl]-2-oxopyrrolidin-1-yl]but-2-enyl]-2,5-dioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile Chemical compound CC1(N(C(N(C1=O)C1=CC(=C(C#N)C=C1)C(F)(F)F)=O)CC=C/CN1C(CC(C1)C1=CC(=C(C=C1)S(=O)(=O)C)C(F)(F)F)=O)C LNPSTXLOXOUAHD-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000001514 prostate carcinoma Diseases 0.000 claims description 2
- JKHBDYKQUSJINX-UHFFFAOYSA-N 4-[1-[(Z)-4-[3-(3-chloro-4-methylsulfonylphenyl)-5,5-dimethyl-2,4-dioxoimidazolidin-1-yl]but-2-enyl]-3-hydroxypyrrolidin-3-yl]-2-(trifluoromethyl)benzonitrile Chemical compound ClC=1C=C(C=CC1S(=O)(=O)C)N1C(N(C(C1=O)(C)C)CC=C/CN1CC(CC1)(O)C1=CC(=C(C#N)C=C1)C(F)(F)F)=O JKHBDYKQUSJINX-UHFFFAOYSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 108
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 81
- 238000006243 chemical reaction Methods 0.000 description 78
- 239000000203 mixture Substances 0.000 description 65
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 51
- 235000019439 ethyl acetate Nutrition 0.000 description 47
- 230000002829 reductive effect Effects 0.000 description 41
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 40
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 40
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 39
- 238000002360 preparation method Methods 0.000 description 39
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 36
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 36
- 239000007787 solid Substances 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 33
- 239000002904 solvent Substances 0.000 description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 239000011541 reaction mixture Substances 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 25
- 239000003480 eluent Substances 0.000 description 25
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 238000010898 silica gel chromatography Methods 0.000 description 24
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 21
- 239000000010 aprotic solvent Substances 0.000 description 20
- 239000000284 extract Substances 0.000 description 18
- 239000003208 petroleum Substances 0.000 description 18
- 229910000027 potassium carbonate Inorganic materials 0.000 description 18
- 229910052500 inorganic mineral Inorganic materials 0.000 description 17
- 235000010755 mineral Nutrition 0.000 description 17
- 239000011707 mineral Substances 0.000 description 17
- 238000005160 1H NMR spectroscopy Methods 0.000 description 16
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 16
- 239000012267 brine Substances 0.000 description 16
- 125000006239 protecting group Chemical group 0.000 description 16
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 16
- 235000015320 potassium carbonate Nutrition 0.000 description 15
- 229910000104 sodium hydride Inorganic materials 0.000 description 14
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 13
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 13
- 150000007530 organic bases Chemical class 0.000 description 13
- 229910052938 sodium sulfate Inorganic materials 0.000 description 13
- 235000011152 sodium sulphate Nutrition 0.000 description 13
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- 229910052740 iodine Inorganic materials 0.000 description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 10
- 230000001028 anti-proliverative effect Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 150000003512 tertiary amines Chemical class 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000003054 catalyst Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 229910000024 caesium carbonate Inorganic materials 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 8
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 229910052763 palladium Inorganic materials 0.000 description 7
- 238000002953 preparative HPLC Methods 0.000 description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 description 7
- 235000017550 sodium carbonate Nutrition 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 6
- 239000011630 iodine Substances 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 239000003880 polar aprotic solvent Substances 0.000 description 6
- FQDIANVAWVHZIR-UPHRSURJSA-N (z)-1,4-dichlorobut-2-ene Chemical compound ClC\C=C/CCl FQDIANVAWVHZIR-UPHRSURJSA-N 0.000 description 5
- CYCKLVAQENOQPG-UHFFFAOYSA-N 4-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C(C#N)C(C(F)(F)F)=C1 CYCKLVAQENOQPG-UHFFFAOYSA-N 0.000 description 5
- QOIHZAYTOAGCNP-UHFFFAOYSA-N 4-bromo-2-chloro-1-methylsulfonylbenzene Chemical compound CS(=O)(=O)C1=CC=C(Br)C=C1Cl QOIHZAYTOAGCNP-UHFFFAOYSA-N 0.000 description 5
- RBRTXKYFMXVIER-UHFFFAOYSA-N 4-iodo-2-(trifluoromethyl)benzonitrile Chemical compound FC(F)(F)C1=CC(I)=CC=C1C#N RBRTXKYFMXVIER-UHFFFAOYSA-N 0.000 description 5
- 0 CC([C@](*)*=C1)C=C1NI(CC(C)=[N+])O Chemical compound CC([C@](*)*=C1)C=C1NI(CC(C)=[N+])O 0.000 description 5
- 238000007126 N-alkylation reaction Methods 0.000 description 5
- 230000002280 anti-androgenic effect Effects 0.000 description 5
- 239000000051 antiandrogen Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- IKZPBTORMHHMIU-UHFFFAOYSA-N 4-(1H-pyrazol-4-yl)-2-(trifluoromethyl)benzonitrile Chemical compound N1N=CC(=C1)C1=CC(=C(C#N)C=C1)C(F)(F)F IKZPBTORMHHMIU-UHFFFAOYSA-N 0.000 description 4
- TVOJIBGZFYMWDT-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CNN=C1 TVOJIBGZFYMWDT-UHFFFAOYSA-N 0.000 description 4
- CAIGCKGYTIPTDL-UHFFFAOYSA-N 4-[3-[(Z)-4-chlorobut-2-enyl]-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile Chemical compound ClCC=C/CN1C(N(C(C1(C)C)=O)C1=CC(=C(C#N)C=C1)C(F)(F)F)=O CAIGCKGYTIPTDL-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 4
- 230000029936 alkylation Effects 0.000 description 4
- 238000005804 alkylation reaction Methods 0.000 description 4
- 239000003098 androgen Substances 0.000 description 4
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 4
- 229960002653 nilutamide Drugs 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 4
- GXWUJFVULVUGKR-IHWYPQMZSA-N 1-[(Z)-4-chlorobut-2-enyl]-4-(3-chloro-4-methylsulfonylphenyl)pyrrolidin-2-one Chemical compound ClC=1C=C(C=CC=1S(=O)(=O)C)C1CC(N(C1)C\C=C/CCl)=O GXWUJFVULVUGKR-IHWYPQMZSA-N 0.000 description 3
- FHZISRKNPVUUCW-IHWYPQMZSA-N 1-[(Z)-4-chlorobut-2-enyl]-4-[4-methylsulfonyl-3-(trifluoromethyl)phenyl]pyrrolidin-2-one Chemical compound ClC\C=C/CN1C(CC(C1)C1=CC(=C(C=C1)S(=O)(=O)C)C(F)(F)F)=O FHZISRKNPVUUCW-IHWYPQMZSA-N 0.000 description 3
- SOZGHDCEWOLLHV-UHFFFAOYSA-N 2-(trifluoromethyl)benzonitrile Chemical compound FC(F)(F)C1=CC=CC=C1C#N SOZGHDCEWOLLHV-UHFFFAOYSA-N 0.000 description 3
- RMGYJFDAMUXQIW-UHFFFAOYSA-N 4-[1-[(Z)-4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-2,4-dioxoimidazolidin-1-yl]but-2-enyl]triazol-4-yl]-2-(trifluoromethyl)benzonitrile Chemical compound C(#N)C1=C(C=C(C=C1)C=1N=NN(C1)CC=C/CN1C(N(C(C1(C)C)=O)C1=CC(=C(C#N)C=C1)C(F)(F)F)=O)C(F)(F)F RMGYJFDAMUXQIW-UHFFFAOYSA-N 0.000 description 3
- MLTGGGUFMAQJAZ-UHFFFAOYSA-N 4-[4-methylsulfonyl-3-(trifluoromethyl)phenyl]-1H-pyrazole Chemical compound CS(=O)(=O)C1=C(C=C(C=C1)C=1C=NNC1)C(F)(F)F MLTGGGUFMAQJAZ-UHFFFAOYSA-N 0.000 description 3
- FNOWWJXBBQZUTM-UHFFFAOYSA-N 4-[4-methylsulfonyl-3-(trifluoromethyl)phenyl]pyrrolidin-2-one Chemical compound CS(=O)(=O)C1=C(C=C(C=C1)C1CC(NC1)=O)C(F)(F)F FNOWWJXBBQZUTM-UHFFFAOYSA-N 0.000 description 3
- KMADDVSNZFTXEC-UHFFFAOYSA-N 4-bromo-1-methylsulfanyl-2-(trifluoromethyl)benzene Chemical compound CSC1=CC=C(Br)C=C1C(F)(F)F KMADDVSNZFTXEC-UHFFFAOYSA-N 0.000 description 3
- QPAKWXWOOVDFDE-UHFFFAOYSA-N 4-ethynyl-2-(trifluoromethyl)benzonitrile Chemical compound C(#C)C1=CC(=C(C#N)C=C1)C(F)(F)F QPAKWXWOOVDFDE-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 229940030486 androgens Drugs 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 238000013043 cell viability test Methods 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- JCWIWBWXCVGEAN-UHFFFAOYSA-L cyclopentyl(diphenyl)phosphane;dichloropalladium;iron Chemical compound [Fe].Cl[Pd]Cl.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1 JCWIWBWXCVGEAN-UHFFFAOYSA-L 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000023958 prostate neoplasm Diseases 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000009331 sowing Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- WIZUMTQRUGFUEE-PLNGDYQASA-N 1-[(Z)-4-chlorobut-2-enyl]-3-(3-chloro-4-methylsulfonylphenyl)-5,5-dimethylimidazolidine-2,4-dione Chemical compound ClC=1C=C(C=CC=1S(=O)(=O)C)N1C(N(C(C1=O)(C)C)C\C=C/CCl)=O WIZUMTQRUGFUEE-PLNGDYQASA-N 0.000 description 2
- KUASPTUGCBGXAE-UHFFFAOYSA-N 2-chloro-5-iodo-3-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC(I)=CN=C1Cl KUASPTUGCBGXAE-UHFFFAOYSA-N 0.000 description 2
- JHDCDEHVUADNKQ-UHFFFAOYSA-N 3-(trifluoromethyl)-1h-pyridin-2-one Chemical compound OC1=NC=CC=C1C(F)(F)F JHDCDEHVUADNKQ-UHFFFAOYSA-N 0.000 description 2
- SGLSJXOUFCIRER-UHFFFAOYSA-N 4-(3-chloro-4-methylsulfonylphenyl)pyrrolidin-2-one Chemical compound ClC=1C=C(C=CC1S(=O)(=O)C)C1CC(NC1)=O SGLSJXOUFCIRER-UHFFFAOYSA-N 0.000 description 2
- BDRPFMCLHHITBM-UHFFFAOYSA-N 4-[3-[(Z)-4-(4-bromoimidazol-1-yl)but-2-enyl]-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile Chemical compound BrC=1N=CN(C1)CC=C/CN1C(N(C(C1(C)C)=O)C1=CC(=C(C#N)C=C1)C(F)(F)F)=O BDRPFMCLHHITBM-UHFFFAOYSA-N 0.000 description 2
- HZEQOTOLDGTAPU-UHFFFAOYSA-N 4-[4,4-dimethyl-2,5-dioxo-3-[(Z)-4-(4-phenyltriazol-1-yl)but-2-enyl]imidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile Chemical compound CC1(N(C(N(C1=O)C1=CC(=C(C#N)C=C1)C(F)(F)F)=O)CC=C/CN1N=NC(=C1)C1=CC=CC=C1)C HZEQOTOLDGTAPU-UHFFFAOYSA-N 0.000 description 2
- DJWJDMOGILQESS-UHFFFAOYSA-N 4-bromo-1-methylsulfonyl-2-(trifluoromethyl)benzene Chemical compound CS(=O)(=O)C1=CC=C(Br)C=C1C(F)(F)F DJWJDMOGILQESS-UHFFFAOYSA-N 0.000 description 2
- CNLWPJFTHPGRAM-UHFFFAOYSA-N 4-bromo-2-chloro-1-methylsulfanylbenzene Chemical compound CSC1=CC=C(Br)C=C1Cl CNLWPJFTHPGRAM-UHFFFAOYSA-N 0.000 description 2
- RISOHYOEPYWKOB-UHFFFAOYSA-N 4-bromo-3,5-dimethyl-1h-pyrazole Chemical compound CC1=NNC(C)=C1Br RISOHYOEPYWKOB-UHFFFAOYSA-N 0.000 description 2
- MBHHFPBCQZCGEF-UHFFFAOYSA-N 5-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound CC1(NC(N(C1=O)C=1C=C(C(=NC1)C#N)C(F)(F)F)=O)C MBHHFPBCQZCGEF-UHFFFAOYSA-N 0.000 description 2
- HQWDBQZOEMIFOG-UHFFFAOYSA-N 5-[3-[(Z)-4-chlorobut-2-enyl]-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound ClCC=C/CN1C(N(C(C1(C)C)=O)C=1C=C(C(=NC1)C#N)C(F)(F)F)=O HQWDBQZOEMIFOG-UHFFFAOYSA-N 0.000 description 2
- ACMILMILHHLANU-UHFFFAOYSA-N 5-iodo-3-(trifluoromethyl)-1h-pyridin-2-one Chemical compound OC1=NC=C(I)C=C1C(F)(F)F ACMILMILHHLANU-UHFFFAOYSA-N 0.000 description 2
- 206010069921 Anti-androgen withdrawal syndrome Diseases 0.000 description 2
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LKHLHFRAWNJSDO-UHFFFAOYSA-N FC(C1=C(C#N)C=CC(=C1)C#C[Si](C)(C)C)(F)F Chemical compound FC(C1=C(C#N)C=CC(=C1)C#C[Si](C)(C)C)(F)F LKHLHFRAWNJSDO-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 229910019213 POCl3 Inorganic materials 0.000 description 2
- 229910002666 PdCl2 Inorganic materials 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 150000001879 copper Chemical class 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 229940091173 hydantoin Drugs 0.000 description 2
- 150000001469 hydantoins Chemical class 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000003586 protic polar solvent Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical compound C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 2
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 1
- MJHFEHXRVNTQIL-UHFFFAOYSA-N 1,2-dichloro-4-ethynylbenzene Chemical group ClC1=CC=C(C#C)C=C1Cl MJHFEHXRVNTQIL-UHFFFAOYSA-N 0.000 description 1
- INYLVXLQAFOLKO-PLNGDYQASA-N 1-[(Z)-4-chlorobut-2-enyl]-5,5-dimethyl-3-[4-methylsulfonyl-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione Chemical compound ClC\C=C/CN1C(N(C(C1(C)C)=O)C1=CC(=C(C=C1)S(=O)(=O)C)C(F)(F)F)=O INYLVXLQAFOLKO-PLNGDYQASA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- FVIMUGZVBGCPIR-UHFFFAOYSA-N 3-(3-chloro-4-methylsulfonylphenyl)-5,5-dimethylimidazolidine-2,4-dione Chemical compound ClC=1C=C(C=CC=1S(=O)(=O)C)N1C(NC(C1=O)(C)C)=O FVIMUGZVBGCPIR-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- VIWUGYNOTRXNSL-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-[4-methylsulfonyl-3-(trifluoromethyl)phenyl]-1,3,2-dioxaborolane Chemical compound CC1(OB(OC1(C)C)C1=CC(=C(C=C1)S(=O)(=O)C)C(F)(F)F)C VIWUGYNOTRXNSL-UHFFFAOYSA-N 0.000 description 1
- UJZFYFXZRYOZAF-UHFFFAOYSA-N 4-(3-chloro-4-methylsulfonylphenyl)-1H-pyrazole Chemical compound ClC=1C=C(C=CC1S(=O)(=O)C)C=1C=NNC1 UJZFYFXZRYOZAF-UHFFFAOYSA-N 0.000 description 1
- ZZHOADALIMASIV-PLNGDYQASA-N 4-[1-[(Z)-4-[5,5-dimethyl-3-[4-methylsulfonyl-3-(trifluoromethyl)phenyl]-2,4-dioxoimidazolidin-1-yl]but-2-enyl]pyrazol-4-yl]-2-(trifluoromethyl)benzonitrile Chemical compound CC1(C(N(C(N1C\C=C/CN1N=CC(=C1)C1=CC(=C(C#N)C=C1)C(F)(F)F)=O)C1=CC(=C(C=C1)S(=O)(=O)C)C(F)(F)F)=O)C ZZHOADALIMASIV-PLNGDYQASA-N 0.000 description 1
- HOAHHKYLXBLLKS-ARJAWSKDSA-N 4-[3-[(Z)-4-(2-aminoethylamino)but-2-enyl]-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile Chemical compound NCCNC\C=C/CN1C(N(C(C1(C)C)=O)C1=CC(=C(C#N)C=C1)C(F)(F)F)=O HOAHHKYLXBLLKS-ARJAWSKDSA-N 0.000 description 1
- OCDSVBHGFSRGQH-UHFFFAOYSA-N 4-[4,4-dimethyl-3-[(Z)-4-[4-[4-methylsulfonyl-3-(trifluoromethyl)phenyl]imidazol-1-yl]but-2-enyl]-2,5-dioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile Chemical compound CC1(N(C(N(C1=O)C1=CC(=C(C#N)C=C1)C(F)(F)F)=O)CC=C/CN1C=NC(=C1)C1=CC(=C(C=C1)S(=O)(=O)C)C(F)(F)F)C OCDSVBHGFSRGQH-UHFFFAOYSA-N 0.000 description 1
- AJLIJYGWAXPEOK-UHFFFAOYSA-N 4-bromo-1-fluoro-2-(trifluoromethyl)benzene Chemical compound FC1=CC=C(Br)C=C1C(F)(F)F AJLIJYGWAXPEOK-UHFFFAOYSA-N 0.000 description 1
- CJTIWGBQCVYTQE-UHFFFAOYSA-N 4-bromo-2-chloro-1-fluorobenzene Chemical compound FC1=CC=C(Br)C=C1Cl CJTIWGBQCVYTQE-UHFFFAOYSA-N 0.000 description 1
- YIROYDNZEPTFOL-UHFFFAOYSA-N 5,5-Dimethylhydantoin Chemical compound CC1(C)NC(=O)NC1=O YIROYDNZEPTFOL-UHFFFAOYSA-N 0.000 description 1
- SSNGWMDGDMRASH-UHFFFAOYSA-N 5,5-dimethyl-3-[4-methylsulfonyl-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C(S(C)(=O)=O)C(C(F)(F)F)=C1 SSNGWMDGDMRASH-UHFFFAOYSA-N 0.000 description 1
- FHZALEJIENDROK-UHFFFAOYSA-N 5-bromo-1h-imidazole Chemical compound BrC1=CN=CN1 FHZALEJIENDROK-UHFFFAOYSA-N 0.000 description 1
- SITFWWOAZYOUHJ-UHFFFAOYSA-N 5-ethynyl-5-fluoro-6-methylcyclohexa-1,3-diene Chemical group CC1C=CC=CC1(F)C#C SITFWWOAZYOUHJ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- MKIUBFCZEGJMEC-AATRIKPKSA-N CC/C=C(\C=C)/NI Chemical compound CC/C=C(\C=C)/NI MKIUBFCZEGJMEC-AATRIKPKSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 1
- 239000005751 Copper oxide Substances 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 101100322888 Escherichia coli (strain K12) metL gene Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910000431 copper oxide Inorganic materials 0.000 description 1
- BERDEBHAJNAUOM-UHFFFAOYSA-N copper(I) oxide Inorganic materials [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 description 1
- KRFJLUBVMFXRPN-UHFFFAOYSA-N cuprous oxide Chemical compound [O-2].[Cu+].[Cu+] KRFJLUBVMFXRPN-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- VRTCYIVYMWGZKE-UHFFFAOYSA-N ethyl 3-(3-chloro-4-methylsulfonylphenyl)-4-nitrobutanoate Chemical compound ClC=1C=C(C=CC1S(=O)(=O)C)C(CC(=O)OCC)C[N+](=O)[O-] VRTCYIVYMWGZKE-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- JYLINEYWRRMESM-UHFFFAOYSA-N tert-butyl 3-[4-cyano-3-(trifluoromethyl)phenyl]-3-hydroxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)(C1)C1=CC(=C(C=C1)C#N)C(F)(F)F JYLINEYWRRMESM-UHFFFAOYSA-N 0.000 description 1
- AOCSUUGBCMTKJH-UHFFFAOYSA-N tert-butyl n-(2-aminoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCN AOCSUUGBCMTKJH-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2013/091118 WO2015100617A1 (en) | 2013-12-31 | 2013-12-31 | Novel imidazolidine-2,4-dione derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2725881T3 true ES2725881T3 (es) | 2019-09-30 |
Family
ID=53492968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13900705T Active ES2725881T3 (es) | 2013-12-31 | 2013-12-31 | Nuevos derivados de imidazolidin-2,4-diona |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9975880B2 (enExample) |
| EP (1) | EP3089974B1 (enExample) |
| JP (1) | JP6258508B2 (enExample) |
| CN (1) | CN105849101B (enExample) |
| ES (1) | ES2725881T3 (enExample) |
| RU (1) | RU2650678C2 (enExample) |
| WO (1) | WO2015100617A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5656651A (en) | 1995-06-16 | 1997-08-12 | Biophysica Inc. | Androgenic directed compositions |
| US6472415B1 (en) | 1998-12-18 | 2002-10-29 | Biophysica, Inc. | Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes |
| DE10322108B4 (de) * | 2003-05-09 | 2008-12-11 | Bayer Schering Pharma Aktiengesellschaft | Antiandrogene Pyrrolidine mit tumorhemmender Wirksamkeit |
| SE0403085D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
| EP4385574A3 (en) * | 2006-03-27 | 2024-10-02 | The Regents of the University of California | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
| FR2944524B1 (fr) * | 2009-04-17 | 2012-11-30 | Ipsen Pharma Sas | Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament |
| FR2944525B1 (fr) * | 2009-04-17 | 2011-06-24 | Ipsen Pharma Sas | Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament |
-
2013
- 2013-12-31 ES ES13900705T patent/ES2725881T3/es active Active
- 2013-12-31 JP JP2016543726A patent/JP6258508B2/ja not_active Expired - Fee Related
- 2013-12-31 EP EP13900705.8A patent/EP3089974B1/en not_active Not-in-force
- 2013-12-31 RU RU2016131297A patent/RU2650678C2/ru active
- 2013-12-31 WO PCT/CN2013/091118 patent/WO2015100617A1/en not_active Ceased
- 2013-12-31 CN CN201380081816.5A patent/CN105849101B/zh not_active Expired - Fee Related
- 2013-12-31 US US15/108,746 patent/US9975880B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US9975880B2 (en) | 2018-05-22 |
| RU2650678C2 (ru) | 2018-04-17 |
| EP3089974B1 (en) | 2019-02-20 |
| WO2015100617A1 (en) | 2015-07-09 |
| CN105849101A (zh) | 2016-08-10 |
| US20160318908A1 (en) | 2016-11-03 |
| RU2016131297A (ru) | 2018-02-06 |
| JP6258508B2 (ja) | 2018-01-10 |
| CN105849101B (zh) | 2019-02-19 |
| EP3089974A4 (en) | 2017-06-21 |
| JP2017501193A (ja) | 2017-01-12 |
| EP3089974A1 (en) | 2016-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2955132T3 (es) | Compuestos heterocíclicos sustituidos con amina como inhibidores de EHMT2 y métodos de uso de los mismos | |
| ES2985987T3 (es) | Derivado de N-(aza-aril)ciclolactam-1-carboxamida, método de preparación correspondiente y uso del mismo | |
| ES2886887T3 (es) | Inhibidor de EGFR y preparación y aplicación del mismo | |
| ES2660914T3 (es) | Derivados de 6-(5-hidroxi-1H-pirazol-1-il)nicotinamida y su uso como inhibidores de PHD | |
| JP5808408B2 (ja) | フタラジノンケトン誘導体、その製造法および医薬用途 | |
| ES2731216T3 (es) | Nuevos compuestos | |
| AU2019342102B2 (en) | Compounds for treating certain leukemias | |
| JP2020196726A (ja) | Ｃｄｋ阻害剤としての置換型ヘテロシクリル誘導体 | |
| ES2977656T3 (es) | Inhibidores de KDM1A para el tratamiento de enfermedades | |
| DK2970332T3 (en) | CHEMICAL UNITS | |
| ES2694829T3 (es) | Derivados de benzotriazol trisustituido como inhibidores de dihidroorotato oxigenasa | |
| KR102432420B1 (ko) | (5,6-디하이드로)피리미도[4,5-e]인돌리진 | |
| ES2927021T3 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| ES2971098T3 (es) | Inhibidores de la quinasa 1 que regula la señal de apoptosis y métodos de uso de los mismos | |
| ES2794868T3 (es) | Inhibidores de GLS1 para el tratamiento de enfermedades | |
| AU2014351413B2 (en) | Pyrrolopyrrolone derivatives and their use as BET inhibitors | |
| ES2968804T3 (es) | Derivado de azaarilo, método de preparación del mismo y uso farmacéutico del mismo | |
| KR20120089437A (ko) | 플라빈 유도체 | |
| ES2725881T3 (es) | Nuevos derivados de imidazolidin-2,4-diona | |
| ES2686353T3 (es) | Nuevos derivados de imidazolidino-2,4-diona | |
| WO2024077391A1 (en) | Thiazolo[5,4-d]pyrimidine compounds, compositions comprising them and uses thereof | |
| HK1230615B (en) | Novel imidazolidine-2,4-dione derivatives | |
| BR122023020299A2 (pt) | Composto, uso de um composto, composição farmacêutica e processo para preparação de um composto |